IMR Press / CEOG / Volume 39 / Issue 2 / pii/1630475538148-1048540543

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research
Combination of baclofen and antimuscarinics to reduce voiding difficulty in treating women with overactive bladders
Show Less
1 Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Keelung, Keelung
2 Department of Management Information Systems, National Chung Hsing University, Taichung
3 Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou Chang Gung University College of Medicine, Kwei-Shan, Tao-Yuan (Taiwan)
Clin. Exp. Obstet. Gynecol. 2012, 39(2), 171–174;
Published: 10 June 2012
Abstract

Purposte of study: To evaluate the efficacy of baclofen in combination with antimuscarinics to treat women with an overactive bladder (OAB) with abnormal voiding patterns. Methods: An action research and chart review was conducted in 245 OAB women. Women were prescribed tolterodine or oxybutynin with or without baclofen after urodynamics. The complaint of voiding difficulty was followed up one week later. Results: There was a significant difference in the occurrence of voiding difficulty after antimuscarinic administration in OAB women with abnormal voiding patterns compared with normal patterns (18% vs 4.9%, respectively; p = 0.013). The clinical difference of voiding difficulty after treating with antimuscarinics between both voiding patterns disappeared after adding baclofen (abnormal voiding pattern vs normal pattern; 11.1% vs 5.6%, respectively; p = 1.000). Conclusion: Combined use of baclofen and antimuscarinic agents could reduce voiding difficulty in treating women with overactive bladders with abnormal voiding patterns.
Keywords
Overactive bladder
Antimuscarinics
Urodynamics
Voiding pattern
Baclofen
Share
Back to top